title: Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma.
abstract: OBJECTIVE
  To verify the efficacy of a serum autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 (PHD3) as a serological marker for RCC.
  
  
  METHODS
  Serum samples and surgically resected tumor tissue specimens were obtained from 22 patients with primary RCC, 15 of whom underwent radical nephrectomy and 7 partial nephrectomy. Preoperative serum samples were obtained just before tumor resection. Postoperative serum samples were obtained from 17 patients at least 1 month after tumor removal. Serum samples were also obtained from 26 healthy volunteers. Titers of the anti-PHD3 antibody (Ab) were determined by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  Serum anti-PHD3 Ab titers were significantly higher in patients with RCC than in healthy volunteers (0.610 ± 0.023 vs. 0.591 ± 0.031, P = 0.0001). Using a cutoff point of 0.599, sensitivity, specificity, and positivity for prediction of RCC were 86.4, 57.7, and 63.3%, respectively. In all 17 patients, titers of serum anti-PHD3 were decreased after the surgical resection compared with those before operation (0.622 ± 0.023 vs. 0.580 ± 0.024, P = 0.0003).
  
  
  CONCLUSIONS
  The present study suggests that the anti-PHD3 Ab may be a novel serological marker for RCC and the titer may reflect the tumor burden in each individual.
authors.affiliation: Department of Urology, Sapporo Medical University School of Medicine, S-1, W16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan. zappa@pop12.odn.ne.jp
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Tanaka
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kitamura
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Torigoe
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Hirohashi
authors.forename: Eiji
authors.initials: E
authors.lastname: Sato
authors.forename: Naoya
authors.initials: N
authors.lastname: Masumori
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Sato
authors.forename: Taiji
authors.initials: T
authors.lastname: Tsukamoto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002292:Carcinoma, Renal Cell / Q000276:immunology*; D049308:Dioxygenases / Q000235:genetics / Q000276:immunology*; D005260:Female; D006801:Humans; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases; D007680:Kidney Neoplasms / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000032:analysis; D012372:ROC Curve
chemical_list: D001323:Autoantibodies; D014408:Biomarkers, Tumor; D012333:RNA, Messenger; D049308:Dioxygenases; C488894:EGLN3 protein, human; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases